In today’s episode, we chat with Lucia Huang, the CEO and co-founder of Osmind, an electronic health record software system for treatment resistant mental health practices that is already in over 300 clinics. In this episode, we discuss:How Osmind makes data-driven decisions Osmind’s quick growth in only 2 yearsWhat it will take for insurance to cover ketamine therapy, as well as other psychedelic therapiesCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In today’s episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical.In this episode, we discuss:Tim’s background in healthcare financeInvesting in classic psychedelic compounds vs. 2nd generation compoundsHallmarks of a good first meeting with a prospective investmentCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Today’s episode features Dillan Dinardo and Tom Ray, the co-founders of Mindstate Design Labs. Mindstate has a unique framework to design psychedelic compounds using what they call the “primer probe method.” This method involves combining a known psychedelic with a non-psychedelic compound. Mindstate just raised an $11.5M seed round.In this episode, we discuss:Tom and Dillan’s experience in YCombinator and raising an $11.5M seed roundTom’s friendship with the late psychedelic chemist Alexander ShulginMindstate’s lead programsThe role of mystical states in the healing processCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian Love

Today’s episode features Amy Emerson, the CEO of MAPS Public Benefit Corporation (PBC), which is a fully owned subsidiary of MAPS, and its purpose is to commercialize MDMA-assisted therapy. We discuss the MAPS PBC and it’s business model for MDMA-assisted therapy.In this episode, we discuss:MAPS’ protocol and strategy behind FDA clinical trial for PTSDAmy’s views on the state of the industry, patents, and how to prioritize accessibilityThe unique business model between MAPS and MAPS PBCPsychedelics for kidsCreated by Greg Kubin and Matias SerebrinskyHost: Greg Kubin and Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Focus Does the Girl by Muted Circus

In today’s episode, we discuss what it’s like being a psychologist who owns a psychedelic clinic. Genesee Herzberg is the co-founder of Sage Integrative Health, an integrative clinic in Berkeley, CA that offers ketamine-assisted therapy (KAP), psychotherapy, somatic therapy, and acupuncture. Genesee discusses her holistic approach to healing, and shares her experience bootstrapping her clinic and setting up a non-profit to make KAP more affordable.In this episode, we discuss:Ketamine-assisted psychotherapy and the difference between high and low dose ketamine treatmentsWhat it takes to get a for-profit clinic off the ground while running a non-profit organizationSage Institute’s mission to make ketamine-assisted psychotherapy affordable for everyoneGenesee’s long term goals for the future of psychedelic medicineCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghRead the transcript here.Find us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Flocean by Zack Frank

In today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech companies developing DMT therapies:  Algernon, Psilera, and Pharmadrug.In this episode, we discuss:DMT therapies for organ transplants, stroke patients and substance abuse disordersResearch supporting NN-DMT’s antioxidative and anti-inflammatory effects and the receptors it targetsBeing a private company vs. public company in psychedelicsNN-DMT5-MeO-DMTBioavailabilityDMT transdermal patchSigma-1DonepezilDr. Rick StrassmanAngiogenesisOrphan Drug DesignationCreated by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghRead the transcript here.Find us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Copley Beat by Blue Dot Sessions, Simplify by Little Glass Men, Pedalrider by Blue Dot Sessions, Running Waters by Jason Shaw, and Neon Drip by Blue Dot Sessions

Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.In this episode, we discuss:Lars’ experience overcoming Treatment-Resistant Depression with psilocybinThe nuances of clinical trials and psilocybin dosing protocolsCompass Pathways’ Intellectual Property strategyWhat additional indications and therapies Compass Pathways is interested inLinks to topics discussed in this episode:Compass Pathways, Lars WildeCOMP360SSRI, SNRIChristian Angermayer, Robin Carhart-Harris, Michael PollanVivaneoQuercis PharmaTRD (Therapy-Resistant Depression)Compass Phase 2B TrialJazz PharmaceuticalsCompass Pathways 2 US patentsOregon Psilocybin Therapy Measure 109Read the transcript here.Watch episode 10 on YouTube.Created by Greg Kubin and Matias SerebrinskyHosts: Matias Serebrinsky and Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: River Meditation by Jason Shaw and Thea by Muted Circus

Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO. In this episode, we discuss:How atai went from idea to IPO in 3 yearsAn overview of atai’s drug development programs and enabling technologiesThe platform’s strategy and risksLinks to topics in this episode:Atai life sciencesEtifoxineEsketamine & arketamineAtai’s S-1Psychedelic Pharmacist AssociationCalyx LawPsilocybin Alpha, Noetic Fundkratom, Salvinorin A, BNC210, mitragynineMike Novogratz, Christian Angermayer, George Goldsmith, Ekaterina Malievskaia, Peter ThielPureTech Health, Akili Interactive LabsBT’s DemeRx EpisodeViridia Life Sciences, EmpathBio, Kures, Recognify Life SciencesRead the transcript here.Watch episode 9 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme musi

Today's episode features Deborah Mash, founder and CEO of DemeRx, a clinical stage company developing ibogaine therapies to treat substance use disorders.In this episode, we discuss:The science, experience and the safety behind Ibogaine’s “neurochemical reset”Navigating US drug regulatory system and securing Intellectual PropertyDeborah’s 30 journey through Amsterdam, Miami and the Caribbean aiming to get Ibogaine therapy approvedPartnership with ATAI Life SciencesLinks to topics discussed in this episode:Deborah MashDemeRxIbogaineNoribogaineTabernanthe IbogaBwiti ReligionHoward LotsofSerotonergicsLambarene - promoted as a mental and physical stimulantHabenulaAddiction Expert Gabor MatéRead the transcript here.Watch episode 8 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music by Medita by Crowander, Two Feet by Muted Circus, and Rain On Me by JBlanked.

Today's episode features Zach Haigney, creator of The Trip Report, a newsletter about psychedelics, policy and business.In 2019, Zach started writing The Trip Report and quickly grew his readership by analyzing psychedelic news headlines from every angle. He’s able to break through all the noise and report with a sense of fairness.In this episode, we discuss:Origin story of The Trip ReportThe complexities of clinical trialsDiversity, inclusion and reciprocity in psychedelic companiesLinks to topics discussed in this episode:The Trip ReportZach HaigneyOregon Measure 109 - 2020MAPSCOMPASS PathwaysUsonaPsilocybin AlphaBob Jesse - Council for Spiritual Practices5-HT2ASerotonin SyndromeNorthstar PledgeNagoya ProtocolFree, Prior, and Informed ConsentRead the transcript here.Watch episode 7 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music by Sun Inside by Ketsa and Better Days Ahead by Ketsa